(Q34335868)

1 August 2017

title

Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study (English)

1 reference

generalized anxiety disorder

1 August 2017

0 references

1 reference

1 reference

inferred from title

author name string

Jonathan R T Davidson

1

1 reference

1 August 2017

Anjana Bose

2

1 reference

1 August 2017

Andrew Korotzer

3

1 reference

1 August 2017

Hongjie Zheng

4

1 reference

1 August 2017

publication date

1 January 2004

1 reference

1 August 2017

published in

Depression and Anxiety

1 reference

1 August 2017

volume

19

1 reference

1 August 2017

issue

4

1 reference

1 August 2017

page(s)

234-240

1 reference

Psychiatric comorbidity in patients with generalized anxiety disorder.

1 August 2017

cites work

1 reference

The assessment of anxiety states by rating

21 January 2018

1 reference

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

21 January 2018

1 reference

Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam

21 January 2018

1 reference

Comorbidity of anxiety, phobia, compulsion and depression

21 January 2018

1 reference

7 January 2021

Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline.

1 reference

7 January 2021

The nature of generalized anxiety disorder and pathological worry: current evidence and conceptual models

1 reference

7 January 2021

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients

1 reference

7 January 2021

Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder

1 reference

7 January 2021

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

1 reference

7 January 2021

Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials.

1 reference

7 January 2021

A rating scale for depression

1 reference

7 January 2021

The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer

1 reference

7 January 2021

Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.

1 reference

7 January 2021

A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder

1 reference

7 January 2021

Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder

1 reference

7 January 2021

Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder

1 reference

7 January 2021

Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model

1 reference

7 January 2021

Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine

1 reference

7 January 2021

Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial

1 reference

7 January 2021

Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study.

1 reference

7 January 2021

Use of benzodiazepines in anxiety disorders

1 reference

7 January 2021

Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline

1 reference

7 January 2021

Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care

1 reference

7 January 2021

The effect of citalopram in panic disorder

1 reference

7 January 2021

Phenomenology and course of generalised anxiety disorder.

1 reference

7 January 2021

Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review.

1 reference

7 January 2021

The hospital anxiety and depression scale

1 reference

7 January 2021

Identifiers

DOI

10.1002/DA.10146

1 reference

1 August 2017

1 reference